RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
The molecular weight and charge of GHK-Cu depend on the pH and the number of coordinated ligands. At neutral pH, the peptide typically binds one copper ion, but ternary complexes with other biomolecules can form. Spectroscopic methods such as electron paramagnetic resonance and circular dichroism are used to study the coordination environment. Reports on the exact geometry vary because the complex is dynamic in solution. Researchers often use synthetic GHK-Cu rather than extracted material to control stoichiometry and purity.
GHK-Cu is a coordination complex formed from the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, the terminal amino group, and the deprotonated amide nitrogen. This arrangement creates a square-planar or distorted geometry around the metal center, depending on pH and the presence of competing ligands. The complex occurs naturally in human plasma, saliva, and urine at low concentrations, and its sequence is conserved across many vertebrate species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper-binding tripeptide complex | Includes Gly-His-Lys and Cu(II) |
| Molecular formula | C14H22CuN6O4 | Reported for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility class | Water-soluble; slightly soluble in polar organic solvents | Often prepared as aqueous stock |
| Typical storage | -20 °C, desiccated, protected from light | Limits oxidation and moisture uptake |
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Purity assessment typically involves high-performance liquid chromatography for the peptide and atomic spectroscopy for copper content. The ratio of copper to peptide is a key quality parameter; a value near one indicates proper stoichiometry. Impurities can include free peptide, copper salts, and truncated sequences from synthesis. Because the complex is dynamic, sample preparation and mobile-phase conditions can shift the observed species. Reported purity values therefore depend on the analytical method and should be interpreted with that context.
Characterizing GHK-Cu requires methods that distinguish the intact complex from free peptide and unbound copper. UV-visible absorption around 600 nm provides a rapid check for copper coordination, while circular dichroism reports on peptide secondary structure. Mass spectrometry confirms the peptide mass and can detect copper adducts under carefully controlled conditions. Electron paramagnetic resonance is particularly informative for Cu(II) because it reveals the ligand field symmetry. No single technique fully defines the complex, so laboratories combine orthogonal methods.
Stability of GHK-Cu in solution depends on pH, temperature, buffer composition, and oxygen exposure. The copper center can undergo reduction or dissociation, especially in the presence of strong metal chelators such as EDTA. Aqueous solutions are often prepared fresh or stored frozen to limit degradation. Lyophilized solid is more stable than liquid formulations, but it can absorb moisture and should be kept dry. Light exposure may also affect copper complexes, though the effect is often modest.
=== Topical application === Topically applied sodium hyaluronate can facilitate the absorption of biomacromolecules, i.e. pharmaceuticals, and function like a nanocarrier. Its effects on skin depend on the hyaluronate formulation and skin health: In barrier-deficient skin it restricted the delivery of biomacromolecules to the stratum corneum and viable epidermis. In normal skin, low-molecular weight hyaluronate (5 kDa) enhanced penetration into the epidermis. Transepidermal water loss increased by 55.5% with low-molecular weight, and was reduced by 28% with crosslinked resilient, and by 16% with HMW. Its efficacy against wrinkles has not been tested in clinical trials. Dry, scaly skin, such as that caused by atopic dermatitis, may be treated with lotion or another skin product containing sodium hyaluronate as its active ingredient. After instillation into the lung, higher molecular weight hyaluronate appears to persist longer in the lung but if > 215 kD there was poor lung penetration and mucociliary clearance. Hyaluronate could allow access to lymph nodes draining the pulmonary bed.
=== Effect on the human body === Stable strontium isotopes do not pose a significant health threat because the average human has an intake of about two milligrams a day. Strontium behaves very much like calcium, with a large portion of the strontium accumulating in bone. Calcium and thus strontium is recycled in the body, dissolving then reincorporating into bone. This cycle means eliminating strontium from the body may take a long time. Elimination is faster in adults whose body primarily deposits strontium on bone surfaces. In children strontium get incorporated in to hard bone minerals. The biological half-life of strontium in humans has variously been reported as from 14 to 600 days, 1,000 days, 18 years, 30 years and, at an upper limit, 49 years. The wide-ranging published biological half-life figures are explained by strontium's complex metabolism within the body. However, by averaging all excretion paths, the overall biological half-life is estimated to be about 18 years. The elimination rate of strontium is strongly affected by age and sex, due to differences in bone metabolism. The drug strontium ranelate aids bone growth, increases bone density, and lessens the incidence of vertebral, peripheral, and hip fractures. However, strontium ranelate also increases the risk of venous thromboembolism, pulmonary embolism, and serious cardiovascular disorders, including myocardial infarction. Its use is therefore now restricted.
== Etymology == The U.S. government referred to the atoll as "Eniwetok" until 1974, when it changed its official spelling to "Enewetak" (along with many other Marshall Islands place names, to more properly reflect their pronunciation by the Marshall Islanders).
== External links == "Rusfertide ( Code - C162883 )". EVS Explore. "Rusfertide Acetate ( Code - C180660 )". EVS Explore. Clinical trial number NCT05210790 for "A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)" at ClinicalTrials.gov
== Nicholson atom theory == In 1911 John William Nicholson published a model of the atom based on classical electrodynamics along the lines of J.J. Thomson's plum pudding model but with the negative electrons orbiting a positive nucleus rather than circulating in a sphere. To avoid immediate collapse of this system he required that electrons come in pairs so the rotational acceleration of each electron was matched across the orbit. Nicholson developed his model based on the analysis of astrophysical spectroscopy. He connected the observed spectral line frequencies with the orbits of electrons in his atoms. The connection he adopted associated the atomic electron orbital angular momentum with the Planck constant. Whereas Planck focused on a quantum of energy, Nicholson's angular momentum quantum relates to orbital frequency. This new concept gave Planck constant an atomic meaning for the first time. Nicholson's model is rarely discussed today but it heavily influenced the important Bohr quantum atom model. Nicholson's spectral results were in good agreement with experiment, forcing Bohr to address these results in his subsequent theory. By 1913 Bohr had already shown, from the analysis of alpha particle energy loss, that hydrogen had only a single electron not a matched pair required by Nicholson's model. In his 1913 paper on atoms, Bohr cites Nicholson as finding quantized angular momentum important for the atom. Bohr quantization would associate emission with differences in the energy levels hydrogen rather than being directly related to the orbital frequency.
Sources: en.wikipedia.org
In 2009, in an article for The Atlantic entitled "The Revenge of Karl Marx", Hitchens frames the late-2000s recession in terms of Marx's economic analysis and notes how much Marx admired the capitalist system that he called for the end of, but says that Marx ultimately failed to grasp how revolutionary capitalist innovation was. Hitchens was an admirer of Che Guevara, yet in an essay written in 1997, he distanced himself from Che, and referred to the mythos surrounding him as a "cult". In 2004 he re-emphasized his positive view of Che, commenting that "[Che's] death meant a lot to me and countless like me at the time. He was a role model, albeit an impossible one for us bourgeois romantics insofar as he went and did what revolutionaries were meant to do – fought and died for his beliefs." He continued to regard Leon Trotsky and Vladimir Lenin as great men, and the October Revolution as a necessary event in the modernisation of Russia. In 2005, Hitchens praised Lenin's creation of "secular Russia" and his attacks on the Russian Orthodox Church, describing the church's power as "absolute warren of backwardness and evil and superstition". In God is not Great, Hitchens called Marxism his "own secular faith" that "has been shaken and discarded, not without pain." He referred to his period of Marxist faith as "when I was a Marxist." According to Andrew Sullivan, his last words were "Capitalism, downfall."
=== Overdose issues === In 2007, a nurse at Cedars-Sinai Medical Center mistakenly gave the 12-day-old twins of actor Dennis Quaid a dose of heparin that was 1,000 times the recommended dose for infants. The overdose allegedly arose because the labeling and design of the adult and infant versions of the product were similar. The Quaid family subsequently sued the manufacturer, Baxter Healthcare Corp., and settled with the hospital for $750,000. Prior to the Quaid accident, six newborn babies at Methodist Hospital in Indianapolis, Indiana, were given an overdose. Three of the babies died after the mistake. In July 2008, another set of twins born at Christus Spohn Hospital South, in Corpus Christi, Texas, died after an accidentally administered overdose of the drug. The overdose was due to a mixing error at the hospital pharmacy and was unrelated to the product's packaging or labeling. As of July 2008, the exact cause of the twins' death was under investigation. In March 2010, a two-year-old transplant patient from Texas was given a lethal dose of heparin at the University of Nebraska Medical Center. The exact circumstances surrounding her death are still under investigation.
Peptide nucleic acid (PNA) is an artificially synthesized polymer similar to DNA or RNA. Synthetic peptide nucleic acid oligomers have been used in recent years in molecular biology procedures, diagnostic assays, and antisense therapies. Due to their higher binding strength, it is not necessary to design long PNA oligomers for use in these roles, which usually require oligonucleotide probes of 20–25 bases. The main concern of the length of the PNA-oligomers is to guarantee the specificity. PNA oligomers also show greater specificity in binding to complementary DNAs, with a PNA/DNA base mismatch being more destabilizing than a similar mismatch in a DNA/DNA duplex. This binding strength and specificity also applies to PNA/RNA duplexes. PNAs are not easily recognized by either nucleases or proteases, making them resistant to degradation by enzymes. PNAs are also stable over a wide pH range. Though an unmodified PNA cannot readily cross the cell membrane to enter the cytosol, covalent coupling of a cell penetrating peptide to a PNA can improve cytosolic delivery. PNA is not known to occur naturally but N-(2-aminoethyl)-glycine (AEG), the backbone of PNA, has been hypothesized to be an early form of genetic molecule for life on Earth and is produced by cyanobacteria and is a neurotoxin. PNA was invented by Peter E. Nielsen (Univ. Copenhagen), Michael Egholm (Univ. Copenhagen), Rolf H. Berg (Risø National Lab), and Ole Buchardt (Univ. Copenhagen) in 1991.
Treatment of established atherosclerotic disease may include medications to lower cholesterol such as statins, blood pressure medication, and anticoagulant therapies to reduce the risk of blood clot formation. As the disease state progresses, more invasive strategies are applied, such as percutaneous coronary intervention, coronary artery bypass graft, or carotid endarterectomy. In some individuals, genetic factors are also implicated in the disease process and cause a strongly increased predisposition to development of atherosclerosis. Atherosclerosis generally starts when a person is young and worsens with age. Almost all people are affected to some degree by the age of 65. It is the number one cause of death and disability in developed countries. Though it was first described in 1575, there is evidence suggesting that this disease state is genetically inherent in the broader human population, with its origins tracing back to CMAH genetic mutations that may have occurred more than two million years ago during the evolution of hominin ancestors of modern human beings.
23. Kuivaniemi, Helena, and Gerard Tromp. "Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases." Gene vol. 707 (2019): 151–171. doi:10.1016/j.gene.2019.05.003
Sources: en.wikipedia.org
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.
Yes, the peptide and its copper complex have been detected in human plasma, saliva, and urine. Endogenous concentrations are low, and reported levels change with age and physiological state. The biological significance of those changes is still an active area of study.
GHK refers to the free tripeptide without a bound copper ion. GHK-Cu contains copper(II) coordinated to the same peptide backbone. The presence of copper affects the complex's color, stability, and interaction with biological molecules.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide coordinates the metal through its histidine imidazole, terminal amino group, and amide nitrogen. It is studied in biochemistry and dermatological research.